Distribution of Aerpio Therapeutics, Inc. - Summary of Receivables and Payables Included in Balance Sheet (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Subsidiary or Equity Method Investee [Line Items]
Amounts receivable from Aerpio	$ 57,000	$ 135,000
Amounts payable to Aerpio	3,032,000	714,000
Aerpio Therapeutics, Inc.
Subsidiary or Equity Method Investee [Line Items]
Amounts receivable from Aerpio	57,245	135,339
Amounts payable to Aerpio	$ 7,656	$ 62,735

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant